Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. Because their low molecular mass, bsAbs have short half-lives. To achieve clinical responses, they have to be infused into patients continously, for a long...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Aliperta, R, Cartellieri, M, Feldmann, A, Arndt, C, Koristka, S, Michalk, I, von Bonin, M, Ehninger, A, Bachmann, J, Ehninger, G, Bornhäuser, M, Bachmann, M P
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648523/
https://ncbi.nlm.nih.gov/pubmed/26383821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.73
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados